Actimis Study:
Positive results

Actimis Study

Positive Results

"This is the first time that the results of a randomized clinical study to assess an antithrombotic agent in combination with thrombolysis during the acute phase of ischemic stroke have demonstrated a significant reduction in mortality; this is very likely due to fewer symptomatic intracerebral hemorrhages."

— Professor Mikael Mazighi, Coordinating Investigator of ACTIMIS Study

Key results :

  • Achievement of the study’s primary endpoint, confirming glenzocimab’s very favorable safety profile
  • Reduction in the number of intracerebral hemorrhages and mortality among patients treated with glenzocimab
ACTIMIS Study Results

ESOC 2022 Presentation

AT the 8th EuropeanStroke Organisation Conference (ESOC) on May 6th, 2022, Professor Mikael Mazighi – Coordinating Investigatorfor ACTIMIS, presented the results of ACTIMIS study: "Glenzocimab, a Novel Antithrombotic, is Associated with Reduced Intracranial Hemorrhage and Mortality Rates when Combined with Standard-Of-Care Reperfusion Therapies: The ACTIMIS Study"